The city of Dallas, Texas, currently has 33 active clinical trials seeking participants for Diabetes research studies.
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Recruiting
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar levels as compared to insulin glargine in people with type 2 diabetes who do not have their blood sugar properly controlled with other oral diabetes medicines. Participant will either get IcoSema or insu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Velocity Clinical Res-Dallas, Dallas, Texas +1 locations
Conditions: Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Recruiting
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Dallas Diabetes Research Center, Dallas, Texas
Conditions: Type 2 Diabetes
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Recruiting
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Thyroid Endocrinology & Diabetes PA, Dallas, Texas +1 locations
Conditions: Diabetes Mellitus, Type 2, Obesity
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Velocity Clinical Res-Dallas, Dallas, Texas +3 locations
Conditions: Type 2 Diabetes Mellitus
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Recruiting
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/14/2024
Locations: Labcorp CRU, Dallas, Texas
Conditions: Healthy, Type 2 Diabetes Mellitus
Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics
Recruiting
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to o... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
03/14/2024
Locations: VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas
Conditions: Osteomyelitis, Diabetes, Amputation
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Recruiting
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Gender:
All
Ages:
Between 8 years and 45 years
Trial Updated:
03/13/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Type 1 Diabetes Mellitus
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Thyroid, Endocrinology, and Diabetes, Dallas, Texas +1 locations
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Polypill for Prevention of Cardiomyopathy
Recruiting
This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 50 or 100 mg, and finerenone 10 mg daily. The study duration is 3 months, and participants will be randomized to either polypill therapy or usual care. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypo... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/11/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Type 2 Diabetes, High Blood Pressure
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Texas
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Recruiting
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Thyroid, Endocrinology, and Diabetes (TED) PA, Dallas, Texas
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Dallas Diabetes Research Center, Dallas, Texas
Conditions: Type 2 Diabetes